IKAROS Zinc Finger Family degraders and uses thereof
The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
1. A compound of Formula (V):
or a pharmaceutically acceptable salt thereof,
wherein
R 2 is —H or —F;
R 21 is —H or —F;
R 3 is —H or —F;
R 7 is C 1-8 alkyl or C 3-12 cycloalkyl,
wherein each C 1-8 alkyl or C 3-12 cycloalkyl of R 7 is optionally substituted with one to four Z 2 ,
which may be the same or different; and
each Z 2 is independently deuterium, halogen, C 1-3 alkyl, C 1-3 haloalkyl, or C 6-10 aryl.
2. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound of Formula (V) is a compound of Formula (Va):
3. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein R 2 is —H; R 21 is —H; and R 3 is —H or —F.
4. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein R 7 is C 1-8 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, spiro [2.3]hexyl, bicyclo[3.1.1]heptyl, spiro [3.3]heptyl, spiro [2.5]octyl, bicyclo[3.2.1]octyl, (1R,5S) bicyclo[3.1.0]hexyl, (1R,5S) bicyclo[3.2.0]heptyl, or spiro [2.4]heptyl, each optionally substituted with 1 to 3 Z 2 , which may be the same or different, wherein each Z 2 is independently deuterium, —CH 3 , —C 2 F, —CHF 2 , —CF 3 , —F, or phenyl.
5. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein R 7 is C 1-3 alkyl or cyclohexyl, each optionally substituted with 1 to 2 Z 2 , which may be the same or different, wherein each Z 2 is independently —F or phenyl.
6. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein R 7 is
7. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.